Tags

Type your tag names separated by a space and hit enter

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study.
Clin Nutr. 2005 Dec; 24(6):925-31.CN

Abstract

BACKGROUND

It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects.

AIM

To assess the short- and long-term effects of Lactobacillus reuteri administration on clinical symptoms of IBS.

METHODS

This is a double blind, placebo-controlled 6-month trial. Subjects consumed 1x10(8)cfu/tablet twice a day. The clinical severity of the IBS symptoms was evaluated by the Francis Severity score and the IBS quality-of-life score at study entry and then monthly.

RESULTS

In total, 54 subjects were randomized for treatment and 39 concluded the study. Both groups (treatment and placebo) improved significantly in all the studied parameters with no significant differences between groups. Two parameters, constipation and passing gases, were marginally different between the main groups (P=0.0714 and 0.0971, respectively).

CONCLUSIONS

IBS symptoms did not improve with probiotic treatment with L. reuteri. A strong placebo effect and a lack of uniformity of the IBS population may have hindered a clearer demonstration of the effect.

Authors+Show Affiliations

The Department of Gastroenterology, Sourasky Medical Center, Meir Hospital, Tel-Aviv University, Israel.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16051399

Citation

Niv, Eva, et al. "The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients With Irritable Bowel Syndrome--a Double Blind, Placebo-controlled, Randomized Study." Clinical Nutrition (Edinburgh, Scotland), vol. 24, no. 6, 2005, pp. 925-31.
Niv E, Naftali T, Hallak R, et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24(6):925-31.
Niv, E., Naftali, T., Hallak, R., & Vaisman, N. (2005). The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clinical Nutrition (Edinburgh, Scotland), 24(6), 925-31.
Niv E, et al. The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients With Irritable Bowel Syndrome--a Double Blind, Placebo-controlled, Randomized Study. Clin Nutr. 2005;24(6):925-31. PubMed PMID: 16051399.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. AU - Niv,Eva, AU - Naftali,Timna, AU - Hallak,Ron, AU - Vaisman,Nachum, Y1 - 2005/07/27/ PY - 2005/04/12/received PY - 2005/06/03/accepted PY - 2005/7/30/pubmed PY - 2006/3/11/medline PY - 2005/7/30/entrez SP - 925 EP - 31 JF - Clinical nutrition (Edinburgh, Scotland) JO - Clin Nutr VL - 24 IS - 6 N2 - BACKGROUND: It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects. AIM: To assess the short- and long-term effects of Lactobacillus reuteri administration on clinical symptoms of IBS. METHODS: This is a double blind, placebo-controlled 6-month trial. Subjects consumed 1x10(8)cfu/tablet twice a day. The clinical severity of the IBS symptoms was evaluated by the Francis Severity score and the IBS quality-of-life score at study entry and then monthly. RESULTS: In total, 54 subjects were randomized for treatment and 39 concluded the study. Both groups (treatment and placebo) improved significantly in all the studied parameters with no significant differences between groups. Two parameters, constipation and passing gases, were marginally different between the main groups (P=0.0714 and 0.0971, respectively). CONCLUSIONS: IBS symptoms did not improve with probiotic treatment with L. reuteri. A strong placebo effect and a lack of uniformity of the IBS population may have hindered a clearer demonstration of the effect. SN - 0261-5614 UR - https://www.unboundmedicine.com/medline/citation/16051399/The_efficacy_of_Lactobacillus_reuteri_ATCC_55730_in_the_treatment_of_patients_with_irritable_bowel_syndrome__a_double_blind_placebo_controlled_randomized_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(05)00093-2 DB - PRIME DP - Unbound Medicine ER -